Author

N. Nicolay

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Comparing two case definitions for including severe acute respiratory infection patients in influenza and COVID-19 vaccine effectiveness studies among older adults using the test-negative design: VEBIS hospital network, seven European countries, 2023/24.

INTRODUCTION Two severe acute respiratory infection (SARI) case definitions (CDs) are often used in test-negative design (TND) hospital-based vaccine effectiveness (VE) studies. SARI-CD1 requires ≥1 symptom (cough, fever, shortness of breath, anosmia, ageusia, or dysgeusia); SARI-CD2 requires both fever and cough. Usin...

Diogo F. P. Marques, Jennifer Howard, Marcos Lozano Álvarez et al. · Vaccine · 0 citations

Open access Jul 2026

Adapted XBB.1.5 vaccine effectiveness against severe COVID-19 outcomes among immunocompromised persons in 2023-24 in six European countries: a VEBIS-EHR network study.

Adapted XBB.1.1.5 vaccine provided moderate protection within 120 days after vaccination against severe COVID-19 outcomes among ICPs aged ≥18 years during a period with BA.2.1 replacing the XBB.1.5 variant.

A. Blake, J. Humphreys, K. Olson et al. · Expert Review of Vaccines · 0 citations

Open access Jul 2026

Impact of autumn 2023 and 2024 COVID-19 vaccination in preventing COVID-19 related hospitalisations and deaths in seven EU/EEA countries: a VEBIS-EHR network study

The 2023 and 2024 autumn vaccination campaigns resulted in substantially different numbers of averted COVID-19-related hospitalisations and deaths among older adults, with fewer events averted in 2024, highlighting the impact of vaccination programmes depends not only on VC and VE but also on alignment between vaccinat...

Y. Mansiaux, A. Blake, N. Nicolay et al. · medRxiv · 0 citations